Background
- There is evolving evidence that HER2 low-expressing (1+/2+ IHC) tumors may respond to novel anti-HER2-based therapies.
- We evaluated the frequency and prognostic impact of HER2 expression and its association with ERBB2 genomic alterations in a large database of molecularly profiled tumors from real-world patients (pts).